Modality
mRNA
MOA
Cl18.2
Target
KRASG12D
Pathway
Complement
CFHuntington's
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Jun 2025
Phase 1Current
NCT05618546
242 pts·Huntington's
2017-01→2025-06·Terminated
242 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-249mo agoPh2 Data· Huntington's
2026-10-277mo awayAdCom· Huntington's
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2025-06-24 · 9mo ago
Huntington's
AdCom
2026-10-27 · 7mo away
Huntington's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05618546 | Phase 1/2 | Huntington's | Terminated | 242 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D |